Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced nonresectable granulosa cell ovarian tumors: The GREKO II study.

被引：0
|
作者：
Hurtado, Alicia
Garcia-Donas, Jesus
Garrigos, Laia
Lainez, Nuria
Redondo, Andres
Fernando Cueva, Juan
Santaballa, Ana
Jesus Rubio, Maria
Palaclo, Isabel
Bover, Isabel
Antonio Lopez-Guerrero, Jose
Prieto, Mario
Garcia-Casado, Zaida
Hernando Polo, Susana
Romero, Nuria
Grande, Enrique
机构：
[1] Hosp Univ Fdn Alcorcon, Alcorcon, Spain
[2] Ctr Integral Oncol Clara Campal, Madrid, Spain
[3] Hosp del Mar, Barcelona, Spain
[4] Complejo Hosp Navarra, Pamplona, Spain
[5] Hosp Univ La Paz, Madrid, Spain
[6] Complexo Hosp Univ Santiago de Compostela, Santiago De Compostela, Spain
[7] Hosp Univ La Fe, Valencia, Spain
[8] Politecn La Fe, Valencia, Spain
[9] Hosp Reina Sofia Cordoba, Cordoba, Spain
[10] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain
[11] GEICO, Mallorca, Spain
[12] Son Llatzer Univ Hosp, Mallorca, Spain
[13] Inst Valenciano Oncol, Mol Biol Lab, Valencia, Spain
[14] Ctr Integral Oncol Clara Campal, Madrid, Spain
[15] Fdn Inst Valenciano Oncol, Valencia, Spain
[16] Hosp Univ Ramon Y Cajal, Dept Med Oncol, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps5626
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS5626
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A phase I/II study of safety and efficacy of orteronel (TAK-700), an oral, investigational, nonsteroidal 17,20-lyase inhibitor, with docetaxel and prednisone (DP) in metastatic castration-resistant prostate cancer (mCRPC): Updated phase II results
    Petrylak, Daniel
    Gandhi, Jitendra G.
    Clark, William R.
    Heath, Elisabeth I.
    Lin, Jianqing
    Oh, William K.
    Agus, David B.
    Carthon, Bradley Curtis
    Moran, Susan
    Kong, Ning
    Suri, Ajit
    Bargfrede, Michael
    Liu, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [32] Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
    Hughes, B. G. M.
    Munoz-Couselo, E.
    Mortier, L.
    Bratland, A.
    Gutzmer, R.
    Roshdy, O.
    Mendoza, R. Gonzalez
    Schachter, J.
    Arance, A.
    Grange, F.
    Meyer, N.
    Joshi, A.
    Billan, S.
    Zhang, P.
    Gumuscu, B.
    Swaby, R. F.
    Grob, J. -j.
    ANNALS OF ONCOLOGY, 2021, 32 (10) : 1276 - 1285
  • [33] A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
    Friedlander, Michael
    Hancock, Kenneth C.
    Rischin, Danny
    Messing, Mark J.
    Stringer, Claude A.
    Matthys, Gemma M.
    Ma, Bo
    Hodge, Jeffrey P.
    Lager, Joanne J.
    GYNECOLOGIC ONCOLOGY, 2010, 119 (01) : 32 - 37
  • [34] Open-label phase II trial of everolimus monotherapy in patients with recurrent metastatic and/or unresectable renal cell carcinoma (RCC)
    Tannir, B.
    Hardikar, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Rucaparib for recurrent, locally advanced, or metastatic urothelial carcinoma (mUC): Results from ATLAS, a phase II open-label trial
    Grivas, Petros
    Loriot, Yohann
    Feyerabend, Susan
    Morales-Barrera, Rafael
    Teo, Min Yuen
    Vogelzang, Nicholas J.
    Grande, Enrique
    Zakharia, Yousef
    Adra, Nabil
    Alva, Ajjai Shivaram
    Necchi, Andrea
    Gupta, Sumati
    Josephs, Debra Hannah
    Rodriguez-Vida, Alejo
    Srinivas, Sandy
    Wride, Kenton
    Thomas, Daleen
    Dusek, Rachel
    Nepert, Dale L.
    Chowdhury, Simon
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [36] Trial in progress: A phase I/II, open-label, dose-escalation, safety and tolerability study of NC318 in subjects with advanced or metastatic solid tumors.
    Gutierrez, Martin
    Hamid, Omid
    Shum, Elaine
    Wise, David R.
    Balar, Arjun Vasant
    Weber, Jeffrey S.
    LoRusso, Patricia
    Shafi, Saba
    Rimm, David L.
    Tolcher, Anthony W.
    Basudhar, Debashree
    Dujka, Melanie Elizabeth
    Heller, Kevin N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [37] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Kanai, Fumihiko
    Obi, Shuntaro
    Fujiyama, Shigetoshi
    Shiina, Shuichiro
    Tamai, Hideyuki
    Mochizuki, Hitoshi
    Koike, Yukihiro
    Imamura, Jun
    Yamaguchi, Takayoshi
    Saida, Isamu
    Yokosuka, Osamu
    Omata, Masao
    HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103
  • [38] An open-label, multicenter phase II trial of capecitabine in patients with cisplatin-refractory or relapsed germ cell tumors
    Oechsle, Karin
    Honecker, Friedemann
    Kollmannsberger, Christian
    Rick, Oliver
    Gruenwald, Victor
    Mayer, Frank
    Hartmann, Joerg T.
    Bokemeyer, Carsten
    ANTI-CANCER DRUGS, 2007, 18 (03) : 273 - 276
  • [39] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma
    Fumihiko Kanai
    Shuntaro Obi
    Shigetoshi Fujiyama
    Shuichiro Shiina
    Hideyuki Tamai
    Hitoshi Mochizuki
    Yukihiro Koike
    Jun Imamura
    Takayoshi Yamaguchi
    Isamu Saida
    Osamu Yokosuka
    Masao Omata
    Hepatology International, 2014, 8 : 94 - 103
  • [40] Durvalumab plus Cetuximab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-label, Nonrandomized, Phase II Clinical Trial
    Gulati, Shuchi
    Crist, McKenzie
    Riaz, Muhammed Kashif
    Takiar, Vinita
    Lehn, Maria
    Monroe, Ilaina
    Palackdharry, Sarah
    Kurtzweil, Nicky
    Jandarov, Roman
    Harun, Nusrat
    Wise-Draper, Trisha M.
    CLINICAL CANCER RESEARCH, 2023, 29 (10) : 1906 - 1915
12345